Search

Your search keyword '"Grosch-Wörner, I"' showing total 127 results
Start Over Author "Grosch-Wörner, I"
127 results on '"Grosch-Wörner, I"'

1. HIV-Infektion und AIDS

Author

Wahn, V., Feiterna-Sperling, C., Niehues, T., Grosch-Wörner, I., Lentze, Michael J., editor, Schulte, Franz J., editor, Schaub, Jürgen, editor, and Spranger, Jürgen, editor

Published
2007
Full Text
View/download PDF

3. HIV-Infektion und AIDS

Author

Wahn, U., Grosch-Wörner, I., Lentze, Michael J., editor, Schulte, Franz J., editor, Schaub, Jürgen, editor, and Spranger, Jürgen, editor

Published
2003
Full Text
View/download PDF

8. Aktuelle Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern Konsensus-Statement¶der Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin,¶der Deutschen Gesellschaft für Pädiatrische Infektiologie und¶der Arbeitsgemeinschaft für Pädiatrische Immunologie: Konsensus-Statement¶der Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin,¶der Deutschen Gesellschaft für Pädiatrische Infektiologie und¶der Arbeitsgemeinschaft für Pädiatrische Immunologie

Author

Wahn, V., Bialek, R., Böhler, T., Funk, M., Grosch-Wörner, I., Horneff, G., Notheis, G., and Wintergerst, U.

Published
1998
Full Text
View/download PDF

10. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009

Author

Tariq, S, Townsend, Cl, Cortina Borja, M, Duong, T, Elford, J, Thorne, C, Tookey, Pa, Giaquinto, C, Rampon, O, Mazza, A, De Rossi, A, Grosch Wörner, I, Mok, J, de José MI, Larrú Martínez, B, Scherpbier, Hj, Kreyenbroek, M, Godfried, Mh, Nellen, Fj, Boer, K, Navér, L, Anzén, B, Lidman, K, Levy, J, Barlow, P, Manigart, Y, Hainaut, M, Goetghebuer, T, Brichard, B, De Camps, J, Thiry, N, Deboone, G, Waterloos, H, De Maria, A, Mûr, A, Payà, A, López Vilchez MA, Carreras, R, Valerius, Nh, Rosenfeldt, V, Coll, O, Suy, A, Perez, Jm, Fortuny, C, Boguña, J, Savasi, V, Viganò, A, Giacomet, V, Cerini, C, Raimondi, C, Zuccotti, G, Alberico, S, Rabusin, M, Bernardon, M, Buffolano, W, Tiseo, R, Martinelli, P, Sansone, M, Maruotti, G, Agangi, A, Tibaldi, C, Marini, S, Masuelli, G, Benedetto, Chiara, Niemieç, T, Marczynska, M, Dobosz, S, Popielska, J, Oldakowska, A, Masters, J, Haile Selassie, H, French, C, Shakes, I., National Study of HIV in Pregnancy Childhood, National Study of HIV in Pregnancy, Childhood, Martinelli, Pasquale, Amsterdam institute for Infection and Immunity, Paediatric Infectious Diseases / Rheumatology / Immunology, General Internal Medicine, Infectious diseases, Other Research, Obstetrics and Gynaecology, Tariq, S, Townsend, Cl, Cortina Borja, M, Duong, T, Elford, J, Thorne, C, Tookey, Pa, European Collaborative, Study, Giaquinto C, National Study of HIV in Pregnancy C. h. i. l. d. h. o. o. d., Rampon, O, Mazza, A, De Rossi, A, Grosch Wörner, I, Mok, J, de José, Mi, Larrú Martínez, B, Scherpbier, Hj, Kreyenbroek, M, Godfried, Mh, Nellen, Fj, Boer, K, Navér, L, Anzén, B, Lidman, K, Levy, J, Barlow, P, Manigart, Y, Hainaut, M, Goetghebuer, T, Brichard, B, De Camps, J, Thiry, N, Deboone, G, Waterloos, H, De Maria, A, Mûr, A, Payà, A, López Vilchez, Ma, Carreras, R, Valerius, Nh, Rosenfeldt, V, Coll, O, Suy, A, Perez, Jm, Fortuny, C, Boguña, J, Savasi, V, Viganò, A, Giacomet, V, Cerini, C, Raimondi, C, Zuccotti, G, Alberico, S, Rabusin, M, Bernardon, M, Buffolano, Wilma, Tiseo, R, Martinelli, P, Sansone, M, Maruotti, G, Agangi, A, Tibaldi, C, Marini, S, Masuelli, G, Benedetto, C, Niemieç, T, Marczynska, M, Dobosz, S, Popielska, J, Oldakowska, A, Masters, J, Haile Selassie, H, French, C, and Shakes, I.

Subjects
Adult, Pediatrics, medicine.medical_specialty, Time Factors, HAART, Anti-HIV Agents, HIV Infections, antiretroviral agents, highly active antiretroviral therapy, HIV, pregnancy outcome, viral load, congenital abnormalities, Article, Zidovudine, ANTIRETROVIRAL AGENTS, immune system diseases, Hiv infected, Antiretroviral Therapy, Highly Active, Medicine, Humans, Pharmacology (medical), Pregnancy Complications, Infectious, antiretroviral agents, highly active antiretroviral therapy, HIV, pregnancy outcome, viral load, Pregnancy outcomes, Retrospective Studies, Pregnancy, integumentary system, business.industry, Infant, virus diseases, Retrospective cohort study, medicine.disease, Infectious Disease Transmission, Vertical, CD4 Lymphocyte Count, zidovudine, Europe, Infectious Diseases, In utero, Immunology, Female, pregnancy, business, Viral load, medicine.drug
Abstract

Increasing numbers of women in resource-rich settings are prescribed zidovudine (ZDV)-sparing highly active antiretroviral therapy (HAART) in pregnancy. We compare ZDV-sparing with ZDV-containing HAART in relation to maternal viral load at delivery, mother-to-child transmission (MTCT) of HIV, and congenital abnormality. This is an analysis of data from the National Study of HIV in Pregnancy and Childhood and the European Collaborative Study. Data on 7573 singleton births to diagnosed HIV-infected women between January 2000 and June 2009 were analyzed. Logistic regression models were fitted to estimate adjusted odds ratios (AORs). Overall, 15.8% (1199 of 7573) of women received ZDV-sparing HAART, with increasing use between 2000 and 2009 (P

Published
2011

14. Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption

Author

Ananworanich, J, Melvin, D, Amador, Jt, Childs, T, Medin, G, Boscolo, V, Compagnucci, A, Kanjanavanit, S, Montero, S, Gibb, Dm, PENTA 11 Study Group including Aboulker, J, Babiker, A, Belfrage, E, Bernardi, S, Bologna, R, Burger, D, Butler, K, Castelli Gattinara, G, Castro, H, Clayden, P, Cressey, T, Darbyshire, Jh, Debré, M, de Groot, R, della Negra, M, di Biagio, A, De Rossi, A, Duicelescu, D, Faye, A, Giaquinto, C, Giacomet, V, Grosch Wörner, I, Hainault, M, Klein, N, Lallemant, M, Levy, J, Lyall, H, Marczynska, M, Marques, L, Mardarescu, M, Mellado Peña MJ, Nadal, D, Nastouli, E, Naver, L, Niehues, T, Peckham, C, Pillay, D, Popieska, J, Ramos Amador JT, Rojo Conejo, P, Rosado, L, Rosso, R, Rudin, C, Scherpbier, Hj, Sharland, M, Stevanovic, M, Thorne, C, Tovo, Pier Angelo, Tudor Williams, G, Turkova, A, Valerius, N, Volokha, A, Walker, As, Welch, S, Wintergerst, U, Aboulker, Jp, Burger, Dm, Green, H, Harper, L, Mofenson, L, Moye, J, Saïdi, Y, Cressey, Tr, Jacqz Aigrain, E, Khoo, S, Regazzi, M, Tréluyer, Jm, Ngo Giang Huong, N, Muñoz Fernandez MA, Hill, C, Lepage, P, Pozniak, A, Vella, S, Chêne, G, Vesikari, T, Hadjou, G, Léonardo, S, Riault, Y, Bleier, J, Buck, L, Duong, T, Farrelly, L, Forcat, S, Harrison, L, Horton, J, Johnson, D, Taylor, C, Chalermpantmetagul, S, Peongjakta, R, Khamjakkaew, W, Than in at, K, Chailert, S, Jourdain, G, Le Coeur, S, Floret, D, Costanzo, P, Le Thi TT, Monpoux, F, Mellul, S, Caranta, I, Boudjoudi, N, Firtion, G, Denon, M, Charlemaine, E, Picard, F, Hellier, E, Heuninck, C, Damond, F, Alexandre, G, Tricoire, J, Antras, M, Lachendowier, C, Nicot, F, Krivine, A, Rivaux, D, Notheis, G, Strotmann, G, Schlieben, S, Rampon, O, Zanchetta, M, Ginocchio, F, Viscoli, C, Martino, A, Pontrelli, G, Baldassar, S, Concato, C, Mazza, A, Rossetti, G, Dobosz, S, Oldakowska, A, Popielska, J, Kaflik, M, Stanczak, J, Stanczack, G, Dyda, T, Kruk, M, González Tomé MI, Delgado García, R, Fernandez Gonzalez MT, Mellado Peña, M, Martín Fontelos, P, Garcia Mellado MI, Medina, Af, Ascencion, B, Garcia Bermejo, I, Navarro Gomez DM, Saavedra, J, Prieto, C, Jimenez, Jl, Garcia Torre, A, de José Gómez MI, García Rodriguez MC, Moreno Pérez, D, Núñez Cuadros, E, Asensi Botet, F, Otero Reigada, C, Pérez Tamarit MD, Vilalta, R, Molina Moreno JM, Rainer, T, Schupbach, J, Rutishauser, M, Bunupuradah, T, Butterworth, O, Phasomsap, C, Prasitsuebsai, W, Chuanjaroen, T, Jupimai, T, Ubolyam, S, Phanuphak, P, Puthanakit, T, Pancharoen, C, Mai, C, Namwong, T, Punsakoon, W, Payakachat, S, Chutima, D, Raksasang, M, Foster, C, Hamadache, D, Campbell, S, Newbould, C, Monrose, C, Abdulla, A, Walley, A, Patel, D, Kaye, S, Seery, P, Rankin, A, Wildfire, A, Novelli, V, Shingadia, D, Moshal, K, Flynn, J, Clapson, M, Allen, A, Spencer, L, Rackstraw, C, Ward, B, Parkes, K, Depala, M, Jacobsen, M, Poulsom, H, Barkley, L, Miah, J, Lurie, P, Keane, C, Mcmaster, P, Phipps, M, Orendi, J, Farmer, C, Liebeschuetz, S, Sodeinde, O, Wong, S, Bostock, V, Heath, Y, Scott, S, Gandhi, K, Lewis, P, Daglish, J, Miles, K, Summerhill, L, Subramaniam, B, Weiner, L, Famiglietti, M, Rana, S, Yu, P, Roa, J, Puga, A, Haerry, A., AII - Amsterdam institute for Infection and Immunity, Paediatric Infectious Diseases / Rheumatology / Immunology, and Global Health

Subjects
0301 basic medicine, Male, Pediatrics, medicine.medical_specialty, antiretroviral therapy, children, HIV, neurocognition, neurodevelopment, quality of life, treatment interruption, Immunology and Allergy, Immunology, Infectious Diseases, Adolescent, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Antiretroviral Therapy, HIV Infections, Standard score, 03 medical and health sciences, 0302 clinical medicine, Cognition, Acquired immunodeficiency syndrome (AIDS), Antiretroviral Therapy, Highly Active, Memory span, Medicine, Humans, Highly Active, 030212 general & internal medicine, Child, Wechsler Intelligence Scale for Children, business.industry, Wechsler Adult Intelligence Scale, medicine.disease, 030112 virology, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Treatment Outcome, Anti-Retroviral Agents, Test score, Mann–Whitney U test, Quality of Life, Female, business, Neurocognitive
Abstract

Item does not contain fulltext OBJECTIVE: Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of life (QoL) are important for managing unplanned interruptions and planned interruptions in HIV cure research. DESIGN: Children previously randomized to continuous (continuous ART, n = 41) vs. planned treatment interruption (PTI, n = 47) in the Pediatric European Network for Treatment of AIDS (PENTA) 11 study were enrolled. At study end, PTI children resumed ART. At 1 and 2 years following study end, children were assessed by the coding, symbol search and digit span subtests of Wechsler Intelligence Scale for Children (6-16 years old) or Wechsler Adult Intelligence Scale (>/=17 years old) and by Pediatrics QoL questionnaires for physical and psychological QoL. Transformed scaled scores for neurocognition and mean standardized scores for QoL were compared between arms by t-test and Mann-Whitney U test, respectively. Scores indicating clinical concern were compared (

Published
2016

15. Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation

Author

Yin, D.E., Warshaw, M.G., Miller, W.C., Castro, H., Fiscus, S.A., Harper, L.M., Harrison, L.J., Klein, N.J., Lewis, J., Melvin, A.J., Tudor Williams, G., Mckinney, R.E., Brouwers, P., Costello, D., Ferguson, E., Fiscus, S., Hodge, J., Hughes, M., Jennings, C., Melvin, A., Mckinney, R., Mofenson, L., Warshaw, M., Smith, M., Spector, S., Stiehm, E., Toye, M., Yogev, R., Babiker, A., Compagnucci, A., De Rossi, A., Giaquinto, C., Darbyshire, J., Debré, M., Gibb, D., Harper, L., Harrison, L., Klein, N., Pillay, D., Saidi, Y., Walker, A., Brody, B., Hill, C., Lepage, P., Modlin, J., Poziak, A., Rein, M., Robb, M., Fleming, T., Vella, S., Kim, K., Bologna, R., Mecikovsky, D., Pineda, N., Sen, L., Mangano, A., Marino, S., Galvez, C., Deluchi, G., Zöhrer, B., Zenz, W., Daghofer, E., Pfurtscheller, K., Pabst, B., Gomez, M., Mcneil, P., Jervis, M., Whyms, I., Kwolfe, D., Scott, S., Mussi Pinhata MM, Issac, M., Cervi, M., Negrini, B., Matsubara, T., de Souza CB, Gabaldi, J., Oliveira, R., Sapia, M., Abreu, T., Evangelista, L., Pala, A., Fernandes, I., Farias, I., Melo M, D.F., Carreira, H., Lira, L., Della Negra, M., Queiroz, W., Lian, Y., Pacola, D., Pinto, J., Ferreira, F., Kakehasi, F., Martins, L., Diniz, A., Lobato, V., Diniz, M., Cleto, S., Costa, S., Romeiro, J., Dollfus, C., Tabone, M., Courcoux, M., Vaudre, G., Dehée, A., Schnuriger, A., Le Gueyades, N., De Bortoli, C., Méchinaud, F., Reliquet, V., Arias, J., Rodallec, A., André, E., Falconi, I., Le Pelletier, A., Monpoux, F., Cottalorda, J., Mellul, S., Lachassinne, E., Galimand, J., Rouzioux, C., Chaix, M., Benabadji, Z., Pourrat, M., Firtion, G., Rivaux, D., Denon, M., Boudjoudi, N., Nganzali, F., Krivine, A., Méritet, J., Delommois, G., Norgeux, C., Guérin, C., Floch, C., Marty, L., Hichou, H., Tournier, V., Faye, A., Le Moal, I., Sellier, M., Dehache, L., Damond, F., Leleu, J., Beniken, D., Alexandre Castor, G., Neubert, J., Niehues, T., Laws, H., Huck, K., Gudowius, S., Siepermann, K., Loeffler, H., Bellert, S., Ortwin, A., Notheis, G., Wintergerst, U., Hoffman, F., Werthmann, A., Seyboldt, S., Schneider, L., Bucholz, B., Feiterna Sperling, C., Peiser, C., Nickel, R., Schmitz, T., Piening, T., Müller, C., Warncke, G., Wigger, M., Neubauer, R., Butler, K., Chong, A., Boulger, T., Menon, A., O'Connell, M., Barrett, L., Rochford, A., Goode, M., Hayes, E., Mcdonagh, S., Walsh, A., Doyle, A., Fanning, J., O'Connor, M., Byrne, M., O'Sullivan, N., Hyland, E., Giacomet, V., Viganò, A., Colombo, I., Trabattoni, D., Berzi, A., Badolato, R., Schumacher, F., Bennato, V., Brusati, M., Sorlini, A., Spinelli, E., Filisetti, M., Bertulli, C., Rampon, O., Zanchetta, M., Mazza, A., Stringari, G., Rossetti, G., Bernardi, S., Martino, A., Castelli Gattinara, G., Palma, P., Pontrelli, G., Tchidjou, H., Furcas, A., Frillici, C., Mazzei, A., Zoccano, A., Concato, C., Duiculescu, D., Oprea, C., Tardei, G., Abaab, F., Mardarescu, M., Draghicenoiu, R., Otelea, D., Alecsandru, L., Matusa, R., Rugina, S., Ilie, M., Netescu, S., Florea, C., Voicu, E., Poalelungi, D., Belmega, C., Vladau, L., Chiriac, A., Ramos Amador JT, Gonzalez Tomé MI, Rojo Conejo, P., Fernandez, M., Delgado Garcia, R., Ferrari, J., Garcia Lopez, M., Mellado Peña MJ, Martin Fontelos, P., Jimenez Nacher, I., Muñoz Fernandez MA, Jimenez, J., García Torre, A., Penin, M., Pineiro Perez, R., Garcia Mellado, I., Finn, A., Lajeunesse, M., Hutchison, E., Usher, J., Ball, L., Dunn, M., Sharland, M., Doerholt, K., Storey, S., Donaghy, S., Chakraborty, R., Wells, C., Buckberry, K., Rice, P., Mcmaster, P., Butler, P., O'Connell C, R., Shenton, J., Haley, H., Orendi, J., Stroobant, J., Navarante, L., Archer, P., Mazhude, C., Scott, D., O'Connell, R., Wong, J., Boddy, G., Shackley, F., Lakshman, R., Hobbs, J., Ball, G., Kudesia, G., Bane, J., Painter, D., Sloper, K., Shah, V., Cheng, A., Aali, A., Ball, C., Hawkins, S., Nayagam, D., Waters, A., Doshi, S., Liebeschuetz, S., Sodiende, B., Shingadia, D., Wong, S., Swan, J., Shah, Z., Collinson, A., Hayes, C., King, J., O'Connor, K., Lyall, H., Fidler, K., Walters, S., Foster, C., Hamadache, D., Newbould, C., Monrose, C., Campbell, S., Yeung, S., Cohen, J., Martinez Allier, N., Melvin, D., Dodge, J., Welch, S., Tatum, G., Gordon, A., Kaye, S., Muir, D., Patel, D., Novelli, V., Moshal, K., Lambert, J., Flynn, J., Farrelly, L., Clapson, M., Spencer, L., Depala, M., Jacobsen, M., Segal, S., Pollard, A., Kelly, D., Yeadon, S., Ohene Kena, B., Peng, Y., Dong, T., Jeffries, K., Snelling, M., Smyth, A., Smith, J., Ward, B., Jungmann, E., Ryan, C., Swaby, K., Buckton, A., Smit, E., Abrams, E., Champion, S., Fernandez, A., Calo, D., Garrovillo, L., Swaminathan, K., Alford, T., Frere, M., Navarra, J., Borkowsky, W., Deygoo, S., Hastings, T., Akleh, S., Ilmet, T., Mohan, K., Bowen, G., Emmanuel, P., Lujan Zimmerman, J., Rodriguez, C., Johnson, S., Marion, A., Graisbery, C., Casey, D., Lewis, G., Guzman Cottrill, J., Croteau, R., Acevedo Flores, M., Gonzalez, M., Angeli, L., Fabregas, L., Valentin, P., Weiner, L., Contello, K., Holz, W., Butler, M., Nachman, S., Kelly, M., Ferraro, D., Rana, S., Reed, C., Yeagley, E., Malheiro, A., Roa, J., Neely, M., Kovacs, A., Homans, J., Rodriguez Lozano, Y., Puga, A., Talero, G., Sellers, R., Lawrence, R., Weinberg, G., Murante, B., Laverty, S., Deveikis, A., Batra, J., Chen, T., Michalik, D., Deville, J., Elkins, K., Marks, S., Jackson Alvarez, J., Palm, J., Fineanganofo, I., Keuth, M., Deveikis, L., Tomosada, W., Van Dyke, R., Alchediak, T., Silio, M., Borne, C., Bradford, S., Eloby Childress, S., Nguyen, K., Rathore, M., Alvarez, A., Mirza, A., Mahmoudi, S., Burke, M., Febo, I., Lugo, L., Santos, R., Church, J., Dunaway, T., Rodier, C., Flynn, P., Patel, N., Discenza, S., Donohoe, M., Luzuriaga, K., Picard, D., Kline, M., Paul, M., Shearer, W., Mcmullen, C., Chadwick, E., Cagwin, E., Kabat, K., Dieudonne, A., Palumbo, P., Johnson, J., Gaur, S., Cerracchio, L., Foca, M., Jurgrau, A., Vasquez Bonilla, S., Silva, G., Gershon, A., Sullivan, J., Bryson, Y., Frenkel, L., Nelson, J., Aboulker, J., Hadjou, G., Léonardo, S., Riault, Y., Saïdi, Y., Buck, L., Forcat, S., Horton, J., Johnson, D., Moore, S., Taylor, C., Collins, D., Buskirk, S., Kamara, P., Nesel, C., Johnson, M., Ferreira, A., Tutko, J., Sprenger, H., Britto, P., Powell, C., Dersimonian, R., Handelsman, E., Ananworanich, J., Belfrage, E., Blanche, S., Bohlin, A., Burger, D., Clayden, P., De Groot, R., Di Biagio, A., Grosch Wörner, I., Hainault, M., Lallemant, M., Levy, J., Marczynska, M., Mellado Pena MJ, Nadal, D., Naver, L., Peckham, C., Popieska, J., Rosado, L., Rosso, R., Rudin, C., Scherpbier, H., Stevanovic, M., Thorne, C., Tovo, P., Valerius, N., Poole, C., Cole, S., and Mcculloh, R.J.

Subjects
CD4-Positive T-Lymphocytes, Male, medicine.medical_treatment, HIV (FISIOLOGIA), lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Human immunodeficiency virus (HIV), HIV Infections, medicine.disease_cause, Treatment failure, Settore BIO/13 - Biologia Applicata, Antiretroviral Therapy, Highly Active, immunologic, Child, HIV, child, reconstitution, treatment failure, Adolescent, Anti-HIV Agents, CD4 Lymphocyte Count, Child, Preschool, Female, Follow-Up Studies, HIV-1, Humans, Infant, Infant, Newborn, Follow up studies, Immunosuppression, medicine.medical_specialty, Settore MED/17 - Malattie Infettive, Antiretroviral Therapy, World health, Article, Internal medicine, medicine, Highly Active, Preschool, Settore MED/04 - Patologia Generale, business.industry, Disease progression, Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio, Newborn, Antiretroviral therapy, Confidence interval, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Immunologic, Reconstitution, Pediatrics, Perinatology and Child Health, Immunology, business
Abstract

BACKGROUND: Quantifying pediatric immunologic recovery by highly active antiretroviral therapy (HAART) initiation at different CD4 percentage (CD4%) and age thresholds may inform decisions about timing of treatment initiation. METHODS: HIV-1-infected, HAART-naive children in Europe and the Americas were followed from 2002 through 2009 in PENPACT-1. Data from 162 vertically infected children, with at least World Health Organization “mild” immunosuppression and CD4% RESULTS: Seventy-two percent of baseline immunosuppressed children recovered to normal within 4 years. Compared with “severe” immunosuppression, more children with “mild” immunosuppression (difference 36%, 95% confidence interval [CI]: 22% to 49%) or “advanced” immunosuppression (difference 20.8%, 95% CI: 5.8% to 35.9%) recovered a normal CD4%. For each 5-year increase in baseline age, the proportion of children achieving a normal CD4% declined by 19% (95% CI: 11% to 27%). Combining baseline CD4% and age effects resulted in >90% recovery when initiating HAART with “mild” immunosuppression at any age or “advanced” immunosuppression at age CONCLUSIONS: Initiating HAART at higher CD4% and younger ages maximizes potential for immunologic recovery. Guidelines should weigh immunologic benefits against long-term risks.

Published
2014

16. The management of HCV infected pregnant women and their children European paediatric HCV network

Author

Pembrey, Lucy, Newell, Marie Louise, Tovo, Pier Angelo, Amoroso, A., Bevilaqua, E., Asensi Botet, F., Pereda, A., Balossini, V., Bona, G., Zaffaroni, M., Bandelloni, A., Coscia, A., Fabris, C., Aime, S., Belloni, C., Bossi, G., Salati, B., Boucher, C., Buffolano, W., Butler, K., Roura, L. Cabero, Sanges, J. M. Bertran, Cigna, P., Ciria, L. M., Ginard, C. Servera, Teruel, G. Claret, Fortuny, C., Coll, O., Corrias, A., Ledda, R., Floris, S., De Maria, A., Echeverria, J., Cilla, G., LANARI, MARCELLO, Tridapalli, E., Venturi, V., Fischler, B., Bohlin, A. B., Lindgren, S., Lindh, G., Giacomet, V., Merlo, M., Figini, C., Erba, P., Viganò, A., Hannam, S., Mieli Vergani, G., Hatzakis, A., Inchley, C., Fjaerli, H. O., Maccabruni, A., Marcellini, M., Sartorelli, M. R., Fontelos, P. Martin, Mazza, A., Mok, J. Y. Q., Mûr, A., Viñolas, M., Paternoster, D. M., Grella, P., Polywka, S., Quinti, I., Casadei, A. M., Rojahn, A., Berg, A., Rosso, R., Ferrando, S., Bassetti, D., Contreras, J. Ruiz, Manzanares, A., Extremera, A. Ruiz, Salvini, F., Zuccotti, G. V., Schmitz, T., Grosch Wörner, I., Sperling, C. Feiterna, Piening, T., Vegnente, A., Iorio, R., Versace, A., Lazier, L., Palomba, E., Gabiano, C., Balbo, L., Zanetti, A., Tanzi, E., FALDELLA, GIACOMO, Pembrey, L., Newell, M. L., Tovo, P. A., Amoroso, A., Bevilacqua, E., Asensi Botet, F., Pereda, A., Balossini, V., Bona, G., Zaffaroni, M., Bandelloni, A., Coscia, A., Fabris, C., Iorio, Raffaele, Vegnente, Angela, Pembrey, Lucy, Newell, Marie-Louise, Tovo, Pier-Angelo, Bevilaqua, E., Asensi-Botet, F., Aime, S., Belloni, C., Bossi, G., Salati, B., Boucher, C., Buffolano, W., Butler, K., Roura, L. Cabero, Sanges, J.M. Bertran, Cigna, P., Ciria, L.M., Ginard, C. Servera, Teruel, G. Claret, Fortuny, C., Coll, O., Corrias, A., Ledda, R., Floris, S., De Maria, A., Echeverria, J., Cilla, G., Faldella, Giacomo, Lanari, M., Tridapalli, E., Venturi, V., Fischler, B., Bohlin, A.-B., Lindgren, S., Lindh, G., Giacomet, V., Merlo, M., Figini, C., Erba, P., Viganò, A., Hannam, S., Mieli-Vergani, G., Hatzakis, A., Inchley, C., Fjaerli, H.O., Maccabruni, A., Marcellini, M., Sartorelli, M.R., Fontelos, P. Martin, Mazza, A., Mok, J.Y.Q., Mûr, A., Viñolas, M., Paternoster, D.M., Grella, P., Polywka, S., Quinti, I., Casadei, A.M., Rojahn, A., Berg, A., Rosso, R., Ferrando, S., Bassetti, D., Contreras, J. Ruiz, Manzanares, A., Extremera, A. Ruiz, Salvini, F., Zuccotti, G.V., Schmitz, T., Grosch-Wörner, I., Sperling, C. Feiterna, Piening, T., Vegnente, A., Iorio, R., Versace, A., Lazier, L., Palomba, E., Gabiano, C., Balbo, L., Zanetti, A., and Tanzi, E.

Subjects
Pediatrics, medicine.medical_specialty, Psychological intervention, Breastfeeding, Pregnancy, Prenatal Diagnosis, Diagnosis, medicine, Humans, Prospective Studies, Pregnancy Complications, Infectious, Prospective cohort study, Hepatitis C, Clinical management, Mother-to-child transmission, Paediatric, Follow-up, Hepatology, business.industry, Transmission (medicine), Gastroenterology, Infant, Newborn, virus diseases, Evidence-based medicine, medicine.disease, digestive system diseases, Infectious Disease Transmission, Vertical, Europe, Immunology, Female, Viral disease, business, Diagnosi
Abstract

Background/Aims: As evidence accumulates relating to mother-to-child (vertical) transmission of hepatitis C virus (HCV), it is timely to draw up guidelines for the clinical management of HCV infected pregnant women and their children. Methods: A review of evidence from the European Paediatric HCV Network (EPHN) prospective study of HCV infected women and their children and other published studies. Meeting of EPHN clinical experts to reach a consensus on recommendations for management. Each recommendation was graded according to the level of evidence. Results/conclusions: Although several risk factors for mother-to-child transmission have been identified, none are modifiable and there are currently no interventions available to prevent vertical transmission of HCV. Data on timing of loss of maternal antibodies and reliability of diagnostic tests inform the optimum follow-up schedule for confirmation or exclusion of infection in children born to HCV infected women. Based on the current evidence, routine antenatal screening for HCV should not be introduced and neither elective caesarean section nor avoidance of breastfeeding should be recommended to HCV infected women to prevent mother-to-child transmission of HCV. HCV/HIV co-infected women should follow existing HIV guidelines. © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Published
2005

17. The immunological and virological consequences of planned treatment interruptions in children with HIV infection

Author

Klein, Nigel, Sefe, Delali, Mosconi, Ilaria, Zanchetta, Marisa, Castro, Hannah, Jacobsen, Marianne, Jones, Hannah, Bernardi, Stefania, Pillay, Deenan, Giaquinto, Carlo, Walker, A. Sarah, Gibb, Diana M., De Rossi, Anita, Paediatric, European Network for Treatment of AIDS 11 Trial Team including Aboulker JP, Ananworanich, J, Babiker, A, Belfrage, E, Bernardi, S, Blanche, S, Bohlin, Ab, Bologna, R, Burger, Dm, Butler, K, Castelli Gattinara, G, Castro, H, Clayden, P, Compagnucci, A, Darbyshire, Jh, Debré, M, Faye, A, de Groot, R, della Negra, M, Duiculescu, D, Giaquinto, C, Gibb, Dm, Grosch Wörner, I, Hainault, M, Harper, L, Klein, N, Lallemant, M, Levy, J, Lyall, H, Marczynska, M, Mardarescu, M, Mellado Peña, Mj, Nadal, D, Niehues, T, Peckham, C, Pillay, D, Ramos Amador, Jt, Rosado, L, Rosso, R, Rudin, C, Saidi, Y, Scherpbier, Hj, Sharland, M, Stevanovic, M, Thorne, C, Tovo, Pier Angelo, Tudor Williams, G, Valerius, N, Walker, As, Welch, S, Wintergerst, U, Aboulker, Jp, Mofenson, L, Moye, J, Saïdi, Y, Cressey, Tr, Jacqz Aigrain, E, Khoo, S, Tréluyer, Jm, De Rossi, A, Ngo Giang Huong, N, Muñoz Fernandez, Ma, Hill, C, Lepage, P, Pozniak, A, Vella, S, Hadjou, G, Léonardo, S, Riault, Y, Buck, L, Farrelly, L, Forcat, S, Harrison, L, Horton, J, Johnson, D, Moore, S, Taylor, C, Chalermpantmetagul, S, Peongjakta, R, Chailert, S, Fregonese, F, Jourdain, G, Butler, D, Carlton, C, Collins, D, Kao, G, Van Buskirk, S, Watson, S, Corradini, S, Floret, D, Le Thi, Tt, Monpoux, F, Cottalorda, J, Lefebvre, Jc, Mellul, S, Boudjoudi, N, Firtion, G, Denon, M, Picard, F, Beniken, D, Damond, F, Alexandre, G, Tricoire, J, Nicot, F, Krivine, A, Rivaux, D, Chaix, Ml, Notheis, G, Strotmann, G, Schlieben, S, Rampon, O, Zanchetta, M, Ginocchio, F, Viscoli, C, Martino, A, Pontrelli, G, Concato, C, Mazza, A, Rossetti, G, Dobosz, S, Oldakowska, A, Popielska, J, Kaflik, M, Stanczak, J, Stanczack, G, Dyda, T, González Tomé, Mi, Delgado García, R, Fernandez Gonzalez, Mt, Martín Fontelos, P, Piñeiro Pérez, R, Penin, M, Garcia Mellado, I, Medina, Af, Ascencion, B, Garcia Bermejo, I, Garcia Vela, Ja, Martin Rubio, I, Gurbindo, D, Navarro Gomez, Ml, Jimenez, Jl, Garcia Torre, A, José Gómez, Mi, García Rodriguez, Mc, Moreno Pérez, D, Núñez Cuadros, E, Asensi Botet, F, Pérez, A, Pérez Tamarit, Md, Gobernado Serrano, M, Gonzales Molina, A, Kalhert, C, Dobrovoljac, M, Berger, C, Nobile, G, Reinhard, S, Schupbach, J, Bunupuradah, T, Puthanakit, T, Pancharoen, C, Butterworth, O, Phasomsap, C, Jupimai, T, Ubolyam, S, Phanuphak, P, Mai, C, Kanjanavanit, S, Namwong, T, Chutima, D, Raksasang, M, Foster, C, Hamadache, D, Campbell, S, Newbould, C, Monrose, C, Patel, D, Kaye, S, Seery, P, Wildfire, A, Novelli, V, Shingadia, D, Moshal, K, Flynn, J, Clapson, M, Allen, A, Spencer, L, Depala, M, Jacobsen, M, Mcmaster, P, Phipps, M, Orendi, J, Farmer, C, Liebeschuetz, S, Sodeinde, O, Wong, S, Heath, Y, Scott, S, Gandhi, K, Lewis, P, Daglish, J, Weiner, L, Famiglietti, M, Rana, S, Yu, P, Roa, J, Puga, A, Haerry, A, and Inma, A.

Subjects
CD31, Genetics and Molecular Biology (all), CD4-Positive T-Lymphocytes, Time Factors, T-CELL RECONSTITUTION, ACTIVE ANTIRETROVIRAL THERAPY, STRUCTURED TREATMENT INTERRUPTION, T-CELL RECONSTITUTION, HIV-1-INFECTED CHILDREN, IMMUNE RECONSTITUTION, THYMIC OUTPUT, 1-INFECTED CHILDREN, Adolescent, Anti-Retroviral Agents, CD8-Positive T-Lymphocytes, Child, Child, Preschool, Drug Administration Schedule, HIV Infections, Humans, Immunophenotyping, Lymphocyte Count, Treatment Outcome, Viral Load, Agricultural and Biological Sciences (all), Biochemistry, Genetics and Molecular Biology (all), Medicine (all), Biochemistry, law.invention, IMMUNE RECONSTITUTION, 0302 clinical medicine, Randomized controlled trial, law, 030212 general & internal medicine, HIV-1-INFECTED CHILDREN, 0303 health sciences, Multidisciplinary, ACTIVE ANTIRETROVIRAL THERAPY, 3. Good health, Medicine, Off Treatment, Poverty-related infectious diseases Infectious diseases and international health [N4i 3], THYMIC OUTPUT, Viral load, Research Article, Science, 1-INFECTED CHILDREN, Auto-immunity, transplantation and immunotherapy [N4i 4], 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), medicine, Preschool, 030304 developmental biology, business.industry, medicine.disease, Clinical trial, Immunology, STRUCTURED TREATMENT INTERRUPTION, business, CD8
Abstract

Contains fulltext : 126098.pdf (Publisher’s version ) (Open Access) OBJECTIVES: To evaluate the immunological and viral consequences of planned treatment interruptions (PTI) in children with HIV. DESIGN: This was an immunological and virological sub-study of the Paediatric European Network for Treatment of AIDS (PENTA) 11 trial, which compared CD4-guided PTI of antiretroviral therapy (ART) with continuous therapy (CT) in children. METHODS: HIV-1 RNA and lymphocyte subsets, including CD4 and CD8 cells, were quantified on fresh samples collected during the study; CD45RA, CD45RO and CD31 subpopulations were evaluated in some centres. For 36 (18 PTI, 18 CT) children, immunophenotyping was performed and cell-associated HIV-1 DNA analysed on stored samples to 48 weeks. RESULTS: In the PTI group, CD4 cell count fell rapidly in the first 12 weeks off ART, with decreases in both naive and memory cells. However, the proportion of CD4 cells expressing CD45RA and CD45RO remained constant in both groups. The increase in CD8 cells in the first 12 weeks off ART in the PTI group was predominantly due to increases in RO-expressing cells. PTI was associated with a rapid and sustained increase in CD4 cells expressing Ki67 and HLA-DR, and increased levels of HIV-1 DNA. CONCLUSIONS: PTI in children is associated with rapid changes in CD4 and CD8 cells, likely due to increased cell turnover and immune activation. However, children off treatment may be able to maintain stable levels of naive CD4 cells, at least in proportion to the memory cell pool, which may in part explain the observed excellent CD4 cell recovery with re-introduction of ART.

Published
2013

18. Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe

Author

Bayley, H, Townsend, C, Cortina Borja, M, Thorne, C, Newell, Ml, Giaquinto, Carlo, Rampon, O, Mazza, A, DE ROSSI, Anita, Grosch Wörner, I, Mok, J, de José MI, Larrú Martínez, B, Ma Peña, J, Gonzalez Garcia, J, Arribas Lopez JR, Garcia Rodriguez MC, Asensi Botet, F, Otero, Mc, Pérez Tamarit, D, Scherpbier, Hj, Kreyenbroek, M, Godfried, Mh, Nellen, Fj, Boer, K, Navér, L, Bohlin, Ab, Belfrage, E, Lindgren, S, Levy, J, Barlow, P, Manigart, Y, Hainaut, M, Goetghebuer, T, Brichard, B, De Camps, J, Thiry, N, Deboone, G, Waterloos, H, Viscoli, C, De Maria, A, Bentivoglio, G, Ferrero, S, Gotta, C, Mûr, A, Pàya, A, López Vilchez MA, Carreras, R, Valerius, Nh, Rosenfeldt, V, Coll, O, Suy, A, Perez, Jm, Fortuny, C, Boguña, J, Savasi, V, Fiore, S, Crivelli, M, Viganò, A, Giacomet, V, Cerini, C, Raimondi, C, Zuccotti, G, Alberico, S, Tropea, M, Businelli, C, Taylor, Gp, Lyall, Eg, Penn, Z, Buffolano, W, Tiseo, R, Martinelli, P, Sansone, M, Maruotti, G, Agangi, A, Tibaldi, C, Marini, S, Masuelli, G, Benedetto, C, Niemieç, T, Marczynska, M, Dobosz, S, Popielska, J, Oldakowska, A, Malyuta, R, Semenenko, I, Pilipenko, T., European Collaborative Study in, Eurocoord, Buffolano, Wilma, Bailey, H, Townsend, C, Cortina Borja, M, Thorne, C., European Collaborative, Study, Martinelli, Pasquale, AII - Amsterdam institute for Infection and Immunity, Paediatric Infectious Diseases / Rheumatology / Immunology, General Internal Medicine, Infectious diseases, Other Research, and Obstetrics and Gynaecology

Subjects
Adult, medicine.medical_specialty, Acquired Immunodeficiency Syndrome, HIV, Pregnancy, Antiviral Agents, antiretroviral therapy, Human immunodeficiency virus (HIV), HIV-1 infected women, mother-to-child transmission, risk factors, HIV Infections, medicine.disease_cause, Medical care, Article, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Antiretroviral Therapy, Highly Active, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Disengagement theory, Pregnancy Complications, Infectious, Pharmacology, 030219 obstetrics & reproductive medicine, business.industry, mother-to-child transmission, Prevention of mother to child transmission, medicine.disease, Antiretroviral therapy, Infectious Disease Transmission, Vertical, 3. Good health, Europe, Infectious Diseases, Family medicine, Immunology, HIV-1, Female, business, HIV-1 infected women, Viral load
Abstract

Background Although mother-to-child transmission (MTCT) rates are at an all-time low in Western Europe, potentially preventable transmissions continue to occur. Duration of antenatal combination antiretroviral therapy (ART) is strongly associated with MTCT risk. Methods Data on pregnant HIV-infected women enrolled in the Western and Central European sites of the European Collaborative Study between January 2000 and July 2009 were analysed. The proportion of women receiving no antenatal ART or 1–13 days of treatment was investigated, and associated factors explored using logistic regression models. Results Of 2,148 women, 142 (7%) received no antenatal ART, decreasing from 8% in 2000–2003 to 5% in 2004– 2009 (χ2=8.73; PConclusions Over the last 10 years, around one in 11 women in this study received insufficient antenatal ART, accounting for 40% of MTCTs. One-half of these women were diagnosed before conception, suggesting disengagement from care.

Published
2011

19. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-< 36 months

Author

Paediatric European Network for Treatment of AIDS including Jacqz Aigrain, E, Harrison, L, Zhao, W, Compagnucci, A, Castro, H, Farrelly, L, Saidi, Y, Hamadache, D, Welch, S, Wintergerst, U, Forcat, S, Hadjou, G, Firtion, G, Snowden, W, Giaquinto, C, Gibb, D, Burger, D, Aboulker, Jp, Brothers, C, Gibb, Dm, Jacqz Aigrain, E, Snowdon, W, Lyall, H, Pharo, C, Le Provost, M, Saïdi, Y, Adkison, K, Song, I, Thoofer, N, Yeo, J, Clayden, P, Cressey, Tr, Khoo, S, Tréluyer, Jm, Babiker, A, Bohlin, Ab, Butler, K, Castelli Gattinara, G, Darbyshire, J, Debré, M, Faye, A, de Groot, R, della Negra, M, Duicelescu, D, Grosch Wörner, I, Kind, C, Lallemant, M, Levy, J, Marczynska, M, Peña, Mj, Nadal, D, Niehues, T, Peckham, C, Amador, Jt, Rosado, L, Rudin, C, Scherpbier, H, Sharland, M, Stevanovic, M, Tovo, Pier Angelo, Tudor Williams, G, Valerius, N, Walker, As, and Wintergerst, U.

Subjects
Infectious diseases and international health [NCEBP 13], Human immunodeficiency virus (HIV), HIV Infections, Pharmacology, medicine.disease_cause, 030226 pharmacology & pharmacy, Gastroenterology, 0302 clinical medicine, Abacavir, Pharmacology (medical), 030212 general & internal medicine, Viral, Child, Preschool, Drug Administration Schedule, Drug Therapy, Combination, HIV-1, Humans, Infant, RNA, Viral, Treatment Outcome, Anti-HIV Agents, Dideoxynucleosides, Lamivudine, Reverse Transcriptase Inhibitors, Infectious Diseases, Medicine (all), Child, 3. Good health, Combination, Viral load, medicine.drug, medicine.medical_specialty, Bioequivalence, Article, Invasive mycoses and compromised host [N4i 2], 03 medical and health sciences, Pharmacokinetics, Drug Therapy, Internal medicine, medicine, Dosing, Preschool, business.industry, Poverty-related infectious diseases [N4i 3], Confidence interval, RNA, business
Abstract

Background Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3–Methods Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks treatment with twice-daily abacavir (8 mg/kg) with or without lamivudine (4 mg/kg) underwent plasma pharmacokinetic sampling. Children then switched to once-daily abacavir (16 mg/kg) with or without lamivudine (8 mg/kg), and sampling was repeated 4 weeks later. The area under the plasma concentration– time curve over 24 h (AUC0–24) and the maximum concentration (Cmax) were compared using geometric mean ratios (GMRs); 90% confidence intervals (CIs) within the range of 0.80–1.25 were considered bioequivalent. Results A total of 18 children (4, 6 and 8 in the 3–0–24, once-daily versus twice-daily, was 1.07 (90% CI 0.92–1.23) for abacavir and 0.91 (90% CI 0.79–1.06) for lamivudine. Cmax almost doubled on once-daily versus twice-daily dosing: abacavir and lamivudine GMRs were 2.04 (90% CI 1.73–2.42) and 1.78 (90% CI 1.52–2.09), respectively. At baseline, 12, 24 and 48 weeks, 89%, 94%, 100% and 89% of children had HIV-1 RNAConclusions Bioequivalence was demonstrated on AUC0–24 between twice-daily and once-daily abacavir; very similar AUC0–24 values were seen for twice-daily and once-daily lamivudine. Given that viral load suppression rates were maintained, these data suggest that once-daily abacavir and lamivudine might be an option for children aged 3–

Published
2010

20. Use of neonatal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV is decreasing in Western Europe

Author

England, K., Thorne, C., Giaquinto, C., Rampon, O., D’Elia, R., De Rossi, A., Grosch Wörner, I., Mok, J., de José, I., Laaru ́, A., Bates, I., Salas, A., Ma Peña, J., Gonzalez Garcia, J., Arribas Lo pez, J. R., Garcia Rodriguez, M. C., Asensi Botet, F., Otero, M. C., Pérez Tamarit, D., Scherpbier, H. J., Kreyenbroek, M., Godfried, M. H., Nellen, F. J. B., Boer, K., Bohlin, A. B., Lindgren, S., Anzén, B., Lidman, K., Elfgren, K., Gyllensten, K., Pehrson, P. O., Levy, J., Barlow, P., Manigart, Y., Hainaut, M., Peltier, A., Goetghebuer, T., Ferrazin, A., DE MARIA, Andrea, Bentivoglio, Giorgio, Ferrero, Simone, Gotta, C., Mur, A., Paya, A., López Vilchez, M. A., Carreras, R., Valerius, N. H., Rosenfeldt, V., Jimenez, J., Coll, O., Suy, A., Perez, J. M., Fortuny, C., Boguña, J., Canet, Y., Pardi, G., Ravizza, M., Guerra, B., Lanari, M., Bianchi, S., Bovicelli, L., Prati, E., Duse, M., Scaravelli, G., Stegagno, M., De Santis, M., Savasi, V., Fiore, S., Cri velli, M., Ferrazzi, E., Vigano`, A., Giacomet, V., Frasca, D., Zuccotti, G., Ravagni Probizer, F., Maccabruni, A., Bucceri, A., Rancilio, L., Alberico, S., Rabusin, M., Bernardon, M., Taylor, G. P., Lyall, E. G. H., Penn, Z., Buffolano, W., Tiseo, R., Martinelli, P., Sansone, M., Maruotti, G., Agangi, A., Tibaldi, C., Marini, S., Masuelli, G., Benedetto, C., Marczynska, T. Niemiec ̧ M., Dobosz, S., Popielska, J., and Oldakowska, A.

Subjects
Microbiology (medical), Cart, Pediatrics, medicine.medical_specialty, antiretroviral therapy, HIV Infections, Chemoprevention, Article, Zidovudine, Pregnancy, Medicine, Humans, HIV, pregnancy, Maternal Transmission, business.industry, Infant, Newborn, medicine.disease, Infectious Disease Transmission, Vertical, Europe, Infectious Diseases, Chemoprophylaxis, Cohort, Observational study, Female, business, Viral load, medicine.drug
Abstract

To the Editor: Since the ACTG076 trial results were published in 1994 [1], antiretroviral prophylaxis for the neonate as well as during pregnancy and delivery has been the cornerstone of prevention of mother-to-child transmission (MTCT) of HIV. In the second decade of the combination antiretroviral therapy (cART) era, around 90% of pregnant HIV-infected women in Western Europe receive antenatal cART, for their own health and/or for prevention of MTCT (PMTCT) [2-4]. The rationale for including neonatal prophylaxis in the ACTG076 trial included uncertainty regarding timing of MTCT and the desire to boost the infant’s in utero and intrapartum antiretroviral drug exposure with 6 weeks zidovudine prophylaxis, as a post-exposure prophylaxis (PEP) for newborns not infected with HIV in utero. Observational studies and trials subsequently demonstrated effectiveness of neonatal PEP for infants whose mothers received no antiretroviral drugs [5-7]. No trial data exist comparing the efficacy of different neonatal prophylaxis regimens for infants of women on cART. We investigated trends in neonatal prophylaxis use in the cART era in Western European sites of the European Collaborative Study, a cohort of HIV-infected pregnant women and their children; full methods are described elsewhere [4]. Logistic regression was used to investigate factors associated with receipt of neonatal prophylaxis. Variables considered in the multivariable model were antenatal antiretroviral use, mode of delivery, country and year of delivery, prematurity (

Published
2009

21. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children

Author

Cressey, Tr, Green, H, Khoo, S, Treluyer, Jm, Compagnucci, A, Saidi, Y, Lallemant, M, Gibb, Dm, Burger, Dm, Collaborators: Aboulker JP, Paediatric European Network for Treatment of AIDS II Study G. r. o. u. p., Babiker, A, Blanche, S, Bohlin, Ab, Butler, K, Castelli Gattinara, G, Clayden, P, Darbyshire, Jh, Debré, M, de Groot, R, della Negra, M, Duicelescu, D, Giaquinto, C, Grosch Wörner, I, Kind, C, Levy, J, Lyall, H, Marczynska, M, Mellado Peña MJ, Nadal, D, Niehues, T, Peckham, C, Ramos Amador JT, Rosado, L, Rudin, C, Scherpbier, Hj, Sharland, M, Stevanovic, M, Tovo, Pier Angelo, Tudor Williams, G, Valerius, N, Walker, As, Wintergerst, U, Aboulker, Jp, Harper, L, Klein, N, Mofenson, L, Moye, J, Saïdi, Y, Jacqz Aigrain, E, Tréluyer, Jm, Clerici, M, De Rossi, A, Ngo Giang Huong, N, Muñoz Fernandez MA, Pillay, D, Hill, C, Lepage, P, Pozniak, A, Vella, S, Eliette, V, Hadjou, G, Léonardo, S, Pitrou, C, Riault, Y, Buck, L, Farrelly, L, Johnson, D, Taylor, C, Chalermpantmetagul, S, Peongjakta, R, Chailert, S, Fregonese, F, Jourdain, G, Butler, D, Carlton, C, Collins, D, Kao, G, Van Buskirk, S, Watson, S, Corradini, S, Floret, D, Laplace, J, Monpoux, F, Cottalorda, J, Lefebvre, Jc, Mellul, S, Boudjoudi, N, Firtion, G, Faye, A, Beniken, D, Damond, F, Tricoire, J, Krivine, A, Chaix, Ml, Notheis, G, Strotmann, G, Schlieben, S, Rampon, O, Zanchetta, M, Rosso, R, Repeto, E, Vitale, F, Martino, A, Bernardi, S, Mazza, A, Rossetti, G, Dobosz, S, Oldakowska, A, Popielska, J, Kaflik, M, Stanczak, J, Stanczac, T, González Tomé MI, Delgado García, R, José Mellado Peña, M, Martín Fontelos, P, Piñeiro Pérez, R, Alimenti, A, Penin, M, Gurbindo, D, Navarro Gomez ML, Jimenez, Jl, Prieto, C, de José Gómez MI, García Rodriguez MC, Moreno Pérez, D, Núñéz Cuadros, E, Asensi Botet, F, Pérez, A, Pérez Tamarit MD, Kalhert, C, Schupbach, J, Bunupuradah, T, Ananworanich, J, Phanuphak, P, Intasan, J, Ubolyam, S, Kanjanavanit, S, Namwong, T, Foster, C, Hamadache, D, Campbell, S, Hanley, C, Walsh, C, Kaye, S, Seery, P, Novelli, V, Shingadia, D, Flynn, J, Clapson, M, Jacobsen, M, Mcmaster, P, Hawkes, E, Liebeschuetz, S, Sodeinde, O, Wong, S, Walsh, S, Heath, Y, Weiner, L, Famiglietti, M, Rana, S, Yu, P, Roa, J, Puga, A, Haerry, A, Regazzi, M, Villani, S, Gibbons, S, Jullien, V, Rey, E, Treluye, Jm, Rodríguez Nóvoa, S, Tawon, Y., University of Zurich, and Green, H

Subjects
Cyclopropanes, Male, Time Factors, Infectious diseases and international health [NCEBP 13], HIV Infections, Drug resistance, Pharmacology, THERAPY, PROPHYLAXIS, 2726 Microbiology (medical), chemistry.chemical_compound, Plasma, immune system diseases, Medicine, Child, Reverse-transcriptase inhibitor, RESISTANCE, THERAPY, EXPOSURE, PHARMACOGENETICS, PROPHYLAXIS, virus diseases, Drug holiday, Viral Load, Infectious Diseases, Alkynes, Child, Preschool, Reverse Transcriptase Inhibitors, Female, Viral load, medicine.drug, Microbiology (medical), medicine.medical_specialty, Efavirenz, Nevirapine, Adolescent, CD4-CD8 Ratio, 610 Medicine & health, Article, Invasive mycoses and compromised host [N4i 2], Internal medicine, Drug Resistance, Viral, Humans, Protease inhibitor (pharmacology), EXPOSURE, PHARMACOGENETICS, business.industry, Poverty-related infectious diseases [N4i 3], 2725 Infectious Diseases, Benzoxazines, CD4 Lymphocyte Count, Regimen, chemistry, Withholding Treatment, 10036 Medical Clinic, Mutation, HIV-1, Microbial pathogenesis and host defense [UMCN 4.1], business, RESISTANCE
Abstract

Contains fulltext : 71467.pdf (Publisher’s version ) (Open Access) BACKGROUND: The optimum strategy for stopping treatment with drugs that have different half-lives in a combination regimen to minimize the risk of selecting drug-resistant viruses remains unknown. We evaluated drug concentrations in plasma, human immunodeficiency virus (HIV) load, and development of drug resistance after a planned treatment interruption of a nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regimen in HIV type 1-infected children. METHODS: Children with viral loads or =30% (for children aged 2-6 years) or CD4 cell percentages > or =25% and CD4 cell counts > or =500 cells/microL (for children aged 7-15 years) were randomized to either a planned treatment interruption or to continuous therapy. In the planned treatment interruption arm, either (1) treatment with nevirapine or efavirenz was stopped, and treatment with the remaining drugs was continued for 7-14 days, or (2) nevirapine or efavirenz were replaced by a protease inhibitor, and all drugs were stopped after 7-14 days. Sampling for determination of plasma drug concentrations, measurement of viral load, and drug resistance testing was scheduled at day 0, day 7 (drug concentrations only), day 14, and day 28 after interruption of treatment with an NNRTI. RESULTS: Treatment with an NNRTI was interrupted for 35 children (20 were receiving nevirapine, and 15 were receiving efavirenz). Median time from NNRTI cessation to stopping all drugs was 9 days (range, 6-15 days) for nevirapine and 14 days (range, 6-18 days) for efavirenz. At 7 days, 1 (5%) of 19 and 4 (50%) of 8 children had detectable nevirapine and efavirenz concentrations, respectively; efavirenz remained detectable in 3 (25%) of 12 children at 14 days. At 14 days, viral load was > or =50 copies/mL in 6 of 16 children interrupting treatment with nevirapine (range, 52-7000 copies/mL) and in 2 of 12 children interrupting treatment with efavirenz (range, 120-1600 copies/mL). No new NNRTI mutations were observed. CONCLUSIONS: In children with virological suppression who experienced interruption of treatment with an NNRTI, staggered or replacement stopping strategies for a median of 9 days for nevirapine and 14 days for efavirenz were not associated with the selection of NNRTI resistance mutations.

Published
2008

23. The management of HCV infected pregnant women and their children European paediatric HCV network

Author

Pembrey, L. Newell, M.-L. Tovo, P.-A. Amoroso, A. Bevilaqua, E. Asensi-Botet, F. Pereda, A. Balossini, V. Bona, G. Zaffaroni, M. Bandelloni, A. Coscia, A. Fabris, C. Aime, S. Belloni, C. Bossi, G. Salati, B. Boucher, C. Buffolano, W. Butler, K. Roura, L.C. Sanges, J.M.B. Cigna, P. Ciria, L.M. Ginard, C.S. Teruel, G.C. Fortuny, C. Coll, O. Corrias, A. Ledda, R. Floris, S. De Maria, A. Echeverria, J. Cilla, G. Faldella, G. Lanari, M. Tridapalli, E. Venturi, V. Fischler, B. Bohlin, A.-B. Lindgren, S. Lindh, G. Giacomet, V. Merlo, M. Figini, C. Erba, P. Viganò, A. Hannam, S. Mieli-Vergani, G. Hatzakis, A. Inchley, C. Fjaerli, H.O. Maccabruni, A. Marcellini, M. Sartorelli, M.R. Fontelos, P.M. Mazza, A. Mok, J.Y.Q. Mûr, A. Viñolas, M. Paternoster, D.M. Grella, P. Polywka, S. Quinti, I. Casadei, A.M. Rojahn, A. Berg, A. Rosso, R. Ferrando, S. Bassetti, D. Contreras, J.R. Manzanares, A. Extremera, A.R. Salvini, F. Zuccotti, G.V. Schmitz, T. Grosch-Wörner, I. Sperling, C.F. Piening, T. Vegnente, A. Iorio, R. Versace, A. Lazier, L. Palomba, E. Gabiano, C. Balbo, L. Zanetti, A. Tanzi, E.

Subjects
virus diseases, digestive system diseases
Abstract

Background/Aims: As evidence accumulates relating to mother-to-child (vertical) transmission of hepatitis C virus (HCV), it is timely to draw up guidelines for the clinical management of HCV infected pregnant women and their children. Methods: A review of evidence from the European Paediatric HCV Network (EPHN) prospective study of HCV infected women and their children and other published studies. Meeting of EPHN clinical experts to reach a consensus on recommendations for management. Each recommendation was graded according to the level of evidence. Results/conclusions: Although several risk factors for mother-to-child transmission have been identified, none are modifiable and there are currently no interventions available to prevent vertical transmission of HCV. Data on timing of loss of maternal antibodies and reliability of diagnostic tests inform the optimum follow-up schedule for confirmation or exclusion of infection in children born to HCV infected women. Based on the current evidence, routine antenatal screening for HCV should not be introduced and neither elective caesarean section nor avoidance of breastfeeding should be recommended to HCV infected women to prevent mother-to-child transmission of HCV. HCV/HIV co-infected women should follow existing HIV guidelines. © 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Published
2005

25. Inter-laboratory comparison of HCV-RNA assay results: Implications for multi-centre research

Author

Pembrey, L. Newell, M.-L. Tovo, P.-A. Van Drimmelen, H. Quinti, I. Furlini, G. Galli, S. Meliconi, M.G. Burns, S. Hallam, N. Sönnerborg, A. Cilia, G. Serrano, E. Laccetti, P. Portella, G. Polywka, S. Icardi, G. Bruzzone, B. Balbo, L. Alfarano, A. Amoroso, A. Asensi-Botet, F. Bona, G. Boucher, C. Buffolano, W. Butler, K. Cabero Roura, L. Bertran Sanges, J.M. Cigna, P. Ciria, L.M. Servera Ginard, C. Coll, O. Fortuny, C. Corrias, A. Ledda, R. Floris, S. De Maria, A. Echeverria, J. Cilla, G. Fabris, C. Feiterna Sperling, C. Grosch-Wörner, I. Fischler, B. Bohlin, A.-B. Fjaerli, H.A. Hannam, S. Mieli-Vergani, G. Hatzakis, A. Lanari, M. Papa, I. Venturi, V. Leon Leal, J.A. Lyall, H. Maccabruni, A. Pacati, I. Arlandi, L. Marcellini, M. Martin Fontelos, P. Mazza, A. Mok, J.Y.Q. Mûr, A. Viñolas, M. Palomba, E. Riva, C. Scolfaro, C. Paternoster, D.M. Grella, P. Casadei, A.M. Rojahn, A. Rosso, R. Bassetti, D. Ruiz Contreras, J. Manzanares, A. Ruiz Extremera, A. Souayah, H. Levy, J. Tudor-Williams, G. Vegnente, A. Wejstal, R. Norkrans, G. Zanetti, A. Tanzi, E. Zuccotti, G.V. Zuin, G. Saccani, B. Vigano, A.

Abstract

To investigate whether it is appropriate to assume comparability of hepatitis virus C (HCV)-RNA results across laboratories in multi-centre studies, nine laboratories of the European Paediatric HCV Network participated in an international proficiency study of HCV-RNA assays. A panel of 12 samples of different dilutions and genotypes was sent to each laboratory and tested with qualitative and/or quantitative HCV-RNA assays according to local procedures. Commercial assays were used in seven laboratories and in-house assays in two. All six laboratories in which a commercial qualitative assay was used were proficient, as were four of six runs (in five laboratories) in which a commercial quantitative assay was used. The proficiency of the laboratories where in-house assays were used could not be assessed according to the VQC definition because of differences in the methods used. Overall, there were several false-negative results, but only one false-positive result with a quantitative assay and none with a qualitative assay. The false-negative results may have implications for the diagnosis of infection, and highlight the need for an antibody test to be performed at 18 months to confirm the absence of infection. The results of qualitative assays were generally consistent across laboratories but it was difficult to evaluate and compare the results of quantitative assays. Multivariate analysis of data collected in multi-centre studies should therefore allow for centre and/or assay used. © 2003 Wiley-Liss, Inc.

Published
2003

26. Pregnancy and HIV infection: A european consensus on management

Author

Coll O, Fiore S, Floridia M, Giaquinto C, Grosch-Wörner I, Guiliano M, Lindgren S, Lyall H, Mandelbrot L, Ml, Newell, Peckham C, Rudin C, AUGUSTO ENRICO SEMPRINI, Taylor G, Thorne C, and Pa, Tovo

Subjects
Counseling, Postnatal Care, Anti-HIV Agents, Cesarean Section, Health Status, Drug Resistance, Infant, Newborn, Child Welfare, HIV Infections, Prenatal Care, Infectious Disease Transmission, Vertical, Breast Feeding, Contraception, Pregnancy, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Humans, Patient Compliance, Female, Preconception Care, Pregnancy Complications, Infectious, Child, Infant Nutritional Physiological Phenomena, Zidovudine, Follow-Up Studies
Published
2002

27. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus: European Paediatric Hepatitis C Virus Network

Author

Tovo, P.-A. Newell, M.-L. Coll, O. de Tejada, B.M. Lanari, M. Bosi, I. Papa, I. Zanetti, A. Contreras, J.R. Manzanares, A. Ramos, J.T. Vegnente, A. Iorio, R. Fabris, C. Bandelloni, A.M. Tibaldi, C. Ciria, L.M. Palomba, E. Riva, C. Scolfaro, C. Buffolano, W. Scotese, I. Micco, A. Marcellini, M. Sartorelli, M.R. Mattia, S. Bohlin, A.-B. Fischler, B. Lindgren, S. Lindh, G. Maccabruni, A. Pacati, I. Arlandi, L. Polywka, S. Butler, K. De Maria, A. Bassetti, D. Fioredda, F. Boni, S. Gotta, C. Mazza, A. Grosch-Wörner, I. Sperling, C.F. Quinti, I. Scaravelli, G. Cigna, P. Cilla, G. Echeverria, J. Souayah, H. Grossman, D. Levy, J. Bona, G. Mok, J.Y.Q. Fontelos, P.M. Arrieta, J.V. Asensi-Botet, F. Otero, M.C. Pérez-Tamarit, D. Zuin, G. Saccani, B. Zuccotti, G.V. Riva, E. Gamboni, A. Wejstal, R. Norkrans, G. Scherpbier, H. Mûr, A. Viñolas, M. Extremera, A.R. Roura, L.C. McBertran Sanges, J. McLeon Leal, J.A. Rodriguez, A. Sarrión-Auñón, A. Corrias, A. Boucher, C. Hatzakis, A. Grella, P.

Abstract

Objective: To investigate the effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. Design: Pooled retrospective analysis of prospectively collected data. Sample: Data on hepatitis C virus seropositive mothers and their children identified around delivery were sent from 24 centres of the European Paediatric Hepatitis C Virus Network. Main outcome measures: Hepatitis C virus infection status of children born to hepatitis C virus infected women. Results: A total of 1,474 hepatitis C virus infected women were identified, of whom 503 (35%) were co-infected with HIV. Co-infected women were more than twice as likely to transmit hepatitis C virus to their children than women with hepatitis C virus infection alone. Overall 9.2% (136/1474) of children were hepatitis C virus infected. Among the women with hepatitis C virus infection-only, multivariate analyses did not show a significant effect of mode of delivery and breastfeeding: caesarean section vs vaginal delivery OR = 1.17, P: 0.66; breastfed versus non-breastfed OR = 1.07, P = 0.83. However, HIV co-infected women delivered by caesarean section were 60% less likely to have an infected child than those delivered vaginally (OR = 0.36, P = 0.01) and those who breastfed were about four times more likely to infect their children than those who did not (OR = 6.41, P: 0.03). HIV infected children were three to four times more likely also to be hepatitis C virus infected than children without HIV infection (crude OR = 3.76, 95% CI 1.89-7.41). Conclusions: These results do not support a recommendation of elective caesarean section or avoidance of breastfeeding for women with hepatitis C virus infection only, but the case for HIV infected women undergoing caesarean section delivery and avoiding breastfeeding is strengthened if they are also hepatitis C virus infected.

Published
2001

29. Autorenverzeichnis

Author

Andresen, V., Angenendt, J., Anthoni, C., Appenrodt, B., Arbogast, M., Arco, G., Atta, J., Auer, M., Auernhammer, C., Autenrieth, I.B., Avenhaus, W., Bachem, R., Backmund, M., Bänsch, D., Ballauff, A., Baltzer, J., Barth, J., Batra, A., Bazarra-Castro, M.A., Beck, S., Becker, K., Becker, Karsten, Behr, J., Behrens, A., Belyaev, O., Bender-Götze, Ch., Bengel, J., Benz, M., Haunerschen, von, Berberich, J., Berger, M., Berner, R., Berr, F., S.C., Blank, N., Bleh, C., Blind, Eberhard, Blum, H.E., Bock, N., Bockhorn, M., Böhler, J., Böhm, M., Bokemeyer, D., Bönner, G., Bork, K., Born, G., Brandt, Thomas, Braun, J., Bruch, H.-P., Brümmendorf, T.H., Brüwer, M., Brunnberg, U., Buchfelder, M., Buchkremer, G., Büchler, M.W., Carl, H.-D., Castell, S., Daniels, C., Daum, S., Detter, C., Deuschl, G., Dieckmann, E., Diederich, S., Diehm, C., Diemer, T., Diener, H.C., Diepolder, H., Distler, J., Dörner, T., Prof. Dr., Domagk, D., Domschke, W., Dragu, A., Dralle, H., Dreyling, M., van, P., Dürk, T., Ebert, D., Ehlebracht-König, I., Elger, C.E., Ell, C., Ellinger, J., Emons, G., Engel, O., Enzensberger, W., Epple, H.-J., Erbel, R., Fassnacht, M., Feußner, Hubertus, Fichter, M., Fiegel, P., Filipas, D., Fisang, C., Fisch, M., Fischbach, W., Fischer, N., Fischer, M., Flamme, C.H., Fleckenstein, K., Floege, J., Fluhr, G., Fölsch, U.R., Forsting, M., Fottner, C., Frank, W., Frey, N., Freyberger, H., Friese, K., Frilling, A., habil, PD. Dr., Frommberger, U., Frühmorgen, P., Fuss, Johannes, Gätje, R., Galle, P.R., Geidel, S., Geiß, H.-Ch., Genth, Ekkehard, Gilsbach, J.M., Gingelmaier, A., Goebel, F.-D., Göhl, J., Gökbuget, N., Gold, R., Gonzalez-Carmona, M.A., Gossé, F., Grabitz, K., Greetfeld, M., Gries, F.A., Grosch-Wörner, I., Grüner, N., Grünke, M., Grüters-Kieslich, A., Gülberg, V., Haak, T., Häfner, R., Härter, M., Hagenacker, T., Hahn, S., Hahner, S., Haidl, G., Hammer, M., Hammersen, F., Handrick, W., Hanisch, F., Hansen, M.P., Hanke, Sara, Haschka, J., Hasslacher, C., Hauer, Th., Hauptmann, A., Heckmann, M., Heidbreder, E., Heim, U., Heindel, W., Heitmann, J., Hegenbart, U., Hermann, W., Herrmann, J.M., Herpertz-Dahlmann, B., Heßlinger, B., Heuß, D., Heußner, P., Hiller, E., Hirner, A., Hölscher, A.H., Hölzen, J., Hörl<ce:sup loc='post">†</ce:sup>, W.H., Hörle, S., Hof, H., Hofmann, W.-K., Hohenberger, W., Hohenfellner, U., Holler, E., Holtmann, G., Honegger, J., Hopf, H.C., Horch, R.E., Hornke, I., Hornung, T., Huber, R.M., Hueber, A., Hübner, J., Hummel, R., Irmscher, S., Janßen, O.E., Jelinek, T., Jendrissek, K.A., Jonas, S., Jost, E., Jung, H.H., Kahaly, G.J., Kalden, J.R., Kalff, J., Kapellen, T., Karaus, M., Kastrup, O., Katsoulis, S., Katus, H., Kaudel, C.P., Kaulitz, R., Keck, C., Keller, F., Kellnar, S., Kiehne, K., Kiess, W., Kindermann, M., Kirschbaum, A., Klein, M., Kleindienst, A., Kneitz, C., von Kodolitsch, Y., Köhler, D., Kessler, H.P., Köhler, G., Köhler, H., Köhler, L., Köhler, M., Köhnke, M., Königs, C., Köninger, J., Könsgen-Mustea, D., Köster, R., Kötter, I., Kohne, E., Kolb, H.-J., Koletzko, S., Kollmar, R., Konstantinidis, S., Koop, K., Kopp, H.G., Koschinsky, T., Kramer, H.J., Krauss, J., Kreis, M.E., Kremer, B., Kroemer, H.K., Kröner-Herwig, B., Kroll, P., Külz, A.K., Kuhl, H., Kuipers, J.G., Laaser, M., Lamla, U., Lammert, F., Langer, M., Laß, M., Laukötter, M., Layer, P., Leffler, M., Lehnert, H., Lehrke, M., Lembcke, B., Lerch, M.M., Liebe, S., Lieber, A., Limmroth, V., Lochs, H., Loddenkemper, R., Löhr, J.-M., Löscher, T., Loh, A., Lorenz, H.-M., Lorenz, J., Lügering, N., Luster, M., Lux, G., Luzar, O., Maercker, A., Magdorf, K., Mallmann, P., Marth, T., May, K., Mayerle, J., Meinertz, T., Melichar, V., Merle, U., Meyer, H.J., Meyer, Th., Meyer-Lehnert, H., Meyer-Marcotty, A., Michels, H., Möbius, C., Möddel, G., Möhler, M., Mönnikes, H., Mössner, J., Mohaupt, M.G., Müller, S.C., Müller, S.A., Müller-Lissner, S., Müller-Quernheim, J., Muntau, A., Musholt, T.J., Nacimiento, W., Nattermann, J., Nelles, G., Neubrand, M., Neuhäuser, C., Neuhaus, P., Neumann, P.-A., Neundörfer, B., Nicolai, T., Niebling, W.-B., Niehues, T., Nilius, G., Nolde, J., Noth, J., Olschewski, H., Ostermeyer, J., Ott, C., Pahernik, S., Palmes, D., Pankratius, U., Parhofer, K., Paschke, R., Passlick, B., Pech, O., Pelster, F.W., Petersen, E.E., Petri, E., Pfaffenbach, B., Pfeifer, M., Pfeiffer, T., Pfister, H.W., Diplom-Gesundheitswirt, Pickel, J., Pilatz, A., Pirlich, M., Polykandriotis, E., Pontz, B., Possinger, K., Pohl-Koppe, A., Pohle, T., Prange, H., Prasse, A., Pruß, A., Rädle, J., Raile, K., Randerath, W., Rascher, W., Rauch, B., Raue, F., Raziorruh, B., Rech, J., Regierer, A.C., Reichel, C., Reindl, C., Reinhardt, D., Reißfelder, C., Rendl, J., Reuss-Borst, M., Rieckmann, P., Riedner, C., Rietschel, E., Rijcken, E., Rister, M., Rödder, K., Rogenhofer, S., Roos, F.C., Roos, R., Rosskopf, D., Rudnik-Schöneborn, S., Rudofsky<ce:sup loc='post">†</ce:sup>, G., Ruhnke, M., Ruß, M., Rust, C.F., Saborowski, F., Sailer, M., Salakdeh, M. Sedigh, Samtleben, Walter, Sandmann, W., Sauerbruch, T., Schaal, K.P., Schackert, G., Schäfer-Graf, U., Schäfers, M., Schalhorn, A., Schepp, W., Schetelig, J., Schifferdecker, M., Schipper, J., Schießl, A., Schlegel, U., Schliep, S., Schmid, A., Schmid, P., Schmidt, F., Schmied, B., Schmiegel, W., Schneider, A., Schneider, T., Schneider-Gold, C., Schnürch, H.-G., Schölmerich, J., Schönermarck, U., Schönhofer, B., Schönland, S., Scholz, H., Schopohl, J., Schott, G., Schrader, J., Schraml, A., Schrezenmeier, H., Schuchert, A., Schüßler, G., Schulze-Koops, H., Schuppan, D., Schuster, V., Schwab, S., Schwandner, O., Schwarz, C.H.M., Schwarz, T.F., Schweppe, K.W., Secknus, R., Segerer, S.E., Senninger, N., Serve, H., Seybold, U., Sezer, O., Siegmund, B., Siegmund, W., Siemon, G., Simmen, B.R., Simonetti, G., Sommer, C., Spengler, U., Sprott, H., Stabenow-Lohbauer, U., Stahl, M., Stalla, G., Stallmach, A., Stammschulte, T., Stebler, R., Stein, R., Steven, D., Sticherling, M., Stöhr, M., Strauch, U., Strauss, A., Strauß, H.-G., Stremmel, C., Stremmel, W., Strupp, M., Stüber, E., Stürz, H., Sure, U., Swoboda, B., Taube, C., Thiel, K., Thomssen, C., Thurau, K., Thöne, J., Thüroff, J., Tomiak, C., Toyka, K.V., Tröger, H., Trüeb, R.M., Tryba, M., Uhl, W., Ullerich, H., Unger, L., Vallböhmer, D., van Calker, D., Vloet, T., Voderholzer, U., Völkl, Thomas M.K., Vogel, T., Vogt, P., Wagenlehner, F.E.M., Wagner, A., Wagner, U., Wahn, V., Wallesch, C.W., Watzka, F., Weber, K., Weber, L., Weber, M.M., Wehrmann, T., Weidner, W., Weinke, T., Weiß, M., Weis-Müller, B.T., Weller, Michael, Wenz, F., Werdan, K., Wettstein, M., Wick, M., Wiegratz, I., Willems, S., Wilke, H., Wintergerst, U., Wirth, M., Wolkersdörfer, G.W., Wüster, C., Zabel, F., Zeidler, H., Zeitz, M., Zerres, K., Ziemer, G., Zierz, S., Zimmermann, T., and Zwerina, J.

Published
2015
Full Text
View/download PDF

30. [Intermediate results of a multicenter study in long-term management of HIV exposed and infected children]

Author

Grosch-Wörner I, Bh, Belohradsky, Klaus-Michael Debatin, Enenkel-Stoodt S, Höger P, Landwehr-Dobberstein C, Wahn V, and Wintergerst U

Subjects
Male, AIDS-Related Opportunistic Infections, Infant, Newborn, AIDS Serodiagnosis, Infant, HIV Infections, Survival Rate, Pregnancy, Risk Factors, Child, Preschool, Germany, Humans, Female, Longitudinal Studies, Prospective Studies, Follow-Up Studies, Retrospective Studies
Abstract

In most cases (about 80%) the HIV-infection of children is acquired during pregnancy or birth. Therefore peculiarities for diagnostic procedures and in the natural course of the disease can be expected if compared to AIDS acquired at adult age. Further interesting questions are the frequency of the (vertical) transmission from the infected mother to the child, the influence of mother- and/or child-related factors as well as the method of delivery on this transmission frequency.In order to answer these questions the children of HIV-infected mothers since April 1, 1988 have been examined virologically, immunologically and clinically since birth by 6 study centers according to a standard protocol. The pregnancy data of the mothers have been documented, according to uniform criteria. Pre- or perinatally infected children not known to be antibody-positive at birth have been separately analysed.The frequency of pre/perinatal transmission from the mother to the child is 15.3%, the elective caesarean section seems to lower the transmission rate. Mother and/or infant related cofactors of the transmission could not be defined. In comparison to the control groups of the intrauterine HIV-exposed but not infected children, at birth the HIV-infected children were clinically and immunologically not ill. During their first months some of the infected children had a significant increase of serum IgG. Oral candidiasis, chronic recurrent diarrhoea and bacterial infections are indicator symptoms of beginning HIV-disease. The Minimum-AIDS-Prevalence in the child's first year is 24%. The relatively late AIDS manifestation (3.7 years) and the average value of 28 months of survival in retrospective observed children were a remarkable result.In general, the course of an HIV-infection in children of HIV-positive women in Germany seems to be comparable to results in other countries. The frequency of transmission from mother to child is relatively low (15.3%) and is an important result for maternity care. The caesarean section should be considered. The course of pregnancy must be examined more subtly in order to find out the still unclear causes of transmission. The Minimum-AIDS-Prevalence of 24% and the frequency of HIV-related signs and symptoms of 29% in the child's first year make it necessary to observe these children rather closely during this time.

Published
1993

31. Recommendations for drug development for children

Author

Catapano, M., primary, Manfredi, C., additional, Paolucci, P., additional, Cross, H., additional, Verhamme, K., additional, Mellado Peña, M.J., additional, Grosch-Wörner, I., additional, Knibbe, C., additional, and Ceci, A., additional

Published
2009
Full Text
View/download PDF

33. TEDDY EPMD: A European Paediatric Medicines Database

Author

Felisi, M., primary, Padula, R., additional, Bartoloni, F., additional, Grosch-Wörner, I., additional, Kagedal, B., additional, Mellado Peña, M.J., additional, Parry, J., additional, Stuchlik, A., additional, Verhamme, K., additional, and Ceci, A., additional

Published
2009
Full Text
View/download PDF

37. Relationship between Changes in Thymic Emigrants and Cell-Associated HIV-1 Dna in HIV-1-Infected Children Initiating Antiretroviral Therapy

Author

De Rossi, Anita, Walker, A Sarah, Forni, Davide De, Klein, Nigel, Gibb, Diana M, Aboulker, J-P, Babiker, A, Compagnucci, A, Darbyshire, J, Debré, M, Gersten, M, Giaquinto, C, Gibb, DM, Jones, A, Aboulker, J-P, Babiker, A, Blanche, S, Bohlin, A-B, Butler, K, Castelli-Gattinara, G, Clayden, P, Darbyshire, J, Debré, M, de Groot, R, Faye, A, Giaquinto, C, Gibb, DM, Griscelli, C, Grosch-Wörner, I, Levy, J, Lyall, H, Mellado Pena, M, Nadal, D, Peckham, C, Ramos Amador, JT, Rosado, L, Rudin, C, Scherpbier, H, Sharland, M, Tovo, PA, Valerius, N, Wintergerst, U, Boucher, C, Clerici, M, de Rossi, A, Klein, N, Loveday, C, Muñoz-Fernandez, M, Pillay, D, Rouzioux, C, Babiker, A, Darbyshire, J, Gibb, DM, Harper, L, Johnson, D, Kelleher, P, McGee, L, Poland, A, Walker, AS, Aboulker, J-P, Carrière, I, Compagnucci, A, Debré, M, Eliette, V, Leonardo, S, Moulinier, C, Saidi, Y, Galli, L, Foot, A, Kershaw, H, Caul, O, Tarnow-Mordi, W, Petrie, J, McIntyre, P, Appleyard, K, Gibb, DM, Novelli, V, Klein, N, McGee, L, Ewen, S, Johnson, M, Gibb, DM, Cooper, E, Fisher, T, Barrie, R, Norman, J, King, D, and Larsson-Sciard, E-L

Abstract

Objectives and methods To investigate the relationship between cell-associated HIV-1 dynamics and recent thymic T-cell emigrants, HIV-1 DNA and T-cell receptor rearrangement excision circles (TREC, a marker of recent thymic emigrants) were measured in peripheral blood mononuclear cells in 181 samples from 33 HIV-1-infected children followed for 96 weeks after antiretroviral therapy (ART) initiation.Results At baseline, HIV-1 DNA was higher in children with higher TREC (P=0.02) and was not related to age, CD4 or HIV-1 RNA in multivariate analyses (P>0.3). Overall, TREC increased and HIV-1 DNA decreased significantly after ART initiation, with faster HIV-1 DNA declines in children with higher baseline TREC (P=0.009). The greatest decreases in HIV-1 DNA occurred in children with the smallest increases in TREC levels during ART (P=0.002). However, this inverse relationship between changes in HIV-1 DNA and TREC tended to vary according to the phase of HIV-1 RNA decline (P=0.13); for the same increase in TREC, HIV-1 DNA decline was much smaller during persistent or transient viraemia compared with stable HIV-1 RNA suppression.Conclusions Overall, these findings indicate that TREC levels predict HIV-1 DNA response to ART and suggest that immune repopulation by thymic emigrants adversely affects HIV-1 DNA decline in the absence of persistent viral suppression, possibly by providing a cellular source for viral infection and replication.

Published
2005
Full Text
View/download PDF

38. Abgestufte Chemotherapie und reduzierte Strahlendosis beim Morbus Hodgkin im Kindesalter - Ein Bericht über 170 Patienten der kooperativen Therapiestudie HD 78

Author

Schwarze Ew, Günther Schellong, A. Jobke, M. Wannenmacher, J. Ritter, Jörn Treuner, Grosch-Wörner I, H. Breu, and H. Riehm

Subjects
Oncology, Chemotherapy, medicine.medical_specialty, Hodgkin s, business.industry, medicine.medical_treatment, Disease, Intensity (physics), Radiation therapy, Text mining, Internal medicine, Pediatrics, Perinatology and Child Health, medicine, business
Published
1982

39. Die Chemotherapie des Osteosarkoms

Author

G. Gaedicke, G. Landbeck, Marsmann G, Grosch-Wörner I, G. Delling, and K Winkler

Subjects
Adriblastin, Chemotherapy, medicine.medical_specialty, Ifosfamide, Cyclophosphamide, business.industry, medicine.medical_treatment, Federal republic of germany, General Medicine, medicine.disease, High dose methotrexate, Surgery, medicine, Osteosarcoma, Methotrexate, business, medicine.drug
Abstract

The cyclic chemotherapy scheme OS I/75 was tried in 6 patients with newly diagnosed osteosarcoma and in 3 patients with secondary metastases. The treatment consists of high dose methotrexate, followed by citrovorum-factor rescue, doxorubicine (Adriblastin) and cyclophosphamide (Endoxan). All 6 primary patients are in a continuous remission of 6+ to 21+ months (median 12+ months). The length of remission in the patients with metastases is 5.5+ and 8+ months. The haematological side effects led to an average prolongation of the cycle by 11 days in a planned cycle duration of 42 days. However, they were readily manageable. Among the other side effects two cases of Adriblastin myocardiopathy are remarkable which became apparent after methotrexate and ifosfamide. In order to improve possibilities for treatment regional centralisation of patient care and interdisciplinary and supraregional cooperation of treatment centres are necessary. A prospective treatment programme has been developed for the Federal Republic of Germany and Austria.

Published
1977

40. Beitrag zur juvenilen chronischen myeloischen Leukämie (jCML) - Fallbeschreibung und Verlaufsbeobachtungen bei 9 Patienten

Author

E. Matzke, G. Landbeck, Kurt Winkler, Grosch-Wörner I, A. Poschmann, K. Fischer, and Marsmann G

Subjects
Down syndrome, Pediatrics, medicine.medical_specialty, business.industry, Follow up studies, Myeloid leukemia, medicine.disease, Toxoplasmosis, Pediatrics, Perinatology and Child Health, Fetal hemoglobin, Medicine, Juvenile, Meningeal Neoplasm, business
Published
1980

41. Vorstellung der kooperativen Studie COALL-80 zur Behandlung der akuten lymphoblastischen Leukämie (ALL) im Kindesalter

Author

E. Matzke, J. Müller, Grosch-Wörner I, S. Caspers, G. Landbeck, Hartmut Kabisch, R. Erttmann, and Kurt Winkler

Subjects
Disease free survival, Pediatrics, medicine.medical_specialty, Regimen, Asparaginase, chemistry.chemical_compound, chemistry, business.industry, Pediatrics, Perinatology and Child Health, medicine, Presentation (obstetrics), business, Childhood all
Abstract

The cooperative study COALL-80 is derived from the BFM-78-study. The aim of the study is a reduction of the initial therapy-morbidity and -mortality without loss of efficacy by omitting asparaginase from the four drug-induction regimen and interposing it between induction- and CNS-therapy phase. The expected two years disease free survival rate of a pilot study will be 82%. This finding is hitherto comparable with the BFM-study results.

Published
1981

42. Hamburger ALL-Studien

Author

J. Müller, E. Matzke, Langendorff G, S. Caspers, Kurt Winkler, Grosch-Wörner I, Meissner C, G. Landbeck, Marsmann G, Hartmut Kabisch, Hess A, and Franke Hd

Subjects
medicine.medical_specialty, Disease free survival, Asparaginase, business.industry, Incidence (epidemiology), Newly diagnosed, Surgery, chemistry.chemical_compound, chemistry, Induction therapy, Pediatrics, Perinatology and Child Health, medicine, Lower border, business
Abstract

From 1971 through 1979 145 newly diagnosed patients with ALL have been treated within a series of consecutive studies. Study I corresponds to branch A of the 1972 DAL study. In the following studies the induction therapy has been escalated stepwise with the continuation therapy remaining mostly unchanged. Thereby the disease free survival rates increased from 75 to 94% after one year and from 32 to 60% after 4 years respectively. CNS-relapse mainly occurred during the second year of treatment. Their incidence rose from 5% to more than 10% in connection with a change in the radiation portal. Since another correction of the portals with special consideration of the paramedian lower border of the skull base no more CNS-relapses have been observed until now. The actual cooperative ALL-study follows a modified BFM-protocol with postponed asparaginase in hoping to achieve reduced initial morbidity and at least equal good survival times.

Published
1980

43. Infants born to mothers seropositive for human immunodeficiency virus. Preliminary findings from a multicentre European study

Author

Mok, Jq, Giaquinto, Carlo, DE ROSSI, Anita, Grosch Wörner, I, Ades, Ae, and Peckham, Cs

Subjects
Adult, Male, Risk, Acquired Immunodeficiency Syndrome, Clinical Trials as Topic, Adolescent, HIV Antigens, Substance-Related Disorders, Infant, Newborn, HIV, Infant, HIV Antibodies, Antibodies, Viral, AIDS-Related Complex, Pregnancy, Humans, Female, Pregnancy Complications, Infectious, Antigens, Viral, Maternal-Fetal Exchange, Retrospective Studies
Abstract

As part of a project within the European Community research activities on acquired immunodeficiency syndrome (AIDS), infants born to human-immunodeficiency-virus-seropositive mothers are being followed up from birth. By October, 1986, 71 infants from Padua, Berlin, and Edinburgh had been followed up to a median age of 6 months (range 1-15 months). Symptoms of AIDS or AIDS-related complex (ARC) had developed in 5, 3 of whom had died. The median age at antibody loss was during the 10th month. An estimated 75% will have lost maternal antibody by 12 months, but loss of antibody did not exclude infection confirmed by virus culture. Numbers were too small to draw conclusions about the risk of AIDS/ARC and mode of delivery or breast-feeding. The study suggested that the risk of AIDS/ARC is higher in infants born to mothers who have AIDS symptoms during pregnancy.

Published
1987

44. German-Austrian recommendations for the antiretroviral therapy of HIV-infection (Status May 2004)

Author

Salzberger, B., Marcus, U., Vielhaber, B., Arasteh, K., Gölz, J., Brockmeyer, N. H., Rockstroh, J., Arendt, G., Bader, A., Behrens, G., Beichert, M., Berg, T., Bergmann, F., Bieniek, B., Blauhut, B., Bogner, J., Bockhaus, W., Brodt, H. R., Büscher, U., Buhk, T., Christensen, S., Docrr, H. W., Dupke, S., Esser, S., Fleckenstein, B., Funk, M., Gantke, B., Gellermann, H. J., Goebel, F. -D, Götzenich, A., Grosch-Wörner, I., Lutz Gürtler, Haberl, A., Haerter, G., Harrer, T., Hartmann, M., Helm, E. -B, Heise, W., Hoffmann, C., Hower, M., Husstedt, I., Jablonowski, H., Jägel-Guedes, E., Jäger, H., Karwat, M., Kerkau, T., Kern, P., Klinker, H., Klüfer, P., Knechten, H., Korn, K., Körner, T., Kräusslich, H. -G, Kramer, A., Kremer, H., Kreuter, A., Kurowski, M., Mauruschat, S., Müller, N., Mutz, A., Oette, M., Pfeil, B., Plettenberg, A., Rasokat, H., Reimann, G., Rieger, A., Rieke, A., Rothe, C., Ruf, B., Ruhnke, M., Rump, J. A., Shah, P., Schafberger, A., Schedel, I., Schewe, K., Schottmann, R., Schmalöer, D., Schmied, B., Schmidt, B., Schmidt, R. E., Schneider, T., Schöfer, H., Schranz, D., Sonnenberg-Schwan, U., Staszewski, S., Stellbrink, H. -J, Stocker, H., Stoehr, A., Stoll, M., Tschachler, E., Überla, K., Ulmer, A., Lunzen, J., Vetter, N., Vocks-Hauck, U., Walker, U. A., Weber, S., Werner, A., Wolf, E., Wolf, H., Zangerle, R., Zeitz, M., and Zippel, S.

45. [Multicenter study of long-term management of HIV exposed and HIV infected children. Study organization and aims]

Author

Höger P, Bh, Belohradsky, Klaus-Michael Debatin, Enenkel S, Grosch-Wörner I, Rosendahl C, Kh, Struzyna, and Wahn V

Subjects
Pregnancy, Risk Factors, Germany, West, Infant, Newborn, AIDS Serodiagnosis, Humans, Multicenter Studies as Topic, Female, HIV Infections, Prospective Studies, Pregnancy Complications, Infectious, Combined Modality Therapy, Retrospective Studies
Abstract

In order ot improve and standardize medical and psychosocial care for infants born to HIV-positive mothers, a prospective multicenter study has been initiated at 6 university hospitals in West-Germany in 1987. Aims of the study are: 1) determination of the rate of vertical HIV-transmission, relevant maternal risk factors and the clinical symptomatology of pre-or perinatally acquired HIV-infections, 2) identification of immunological and virological laboratory markers important for the verification and staging of HIV-infections in infants, 3) elaboration of an interdisciplinary approach to the care of HIV-infected children and their families, integrating medical care, social and psychological attendance.

47. A significan sex—but not elective cesarean section—effect on mother-to-child transmission of hepatitis C virus infection

Author

Amoroso, A., Asensi-Botet, F., Pereda, A., Balossini, V., Bona, G., Zaffaroni, M., Bandelloni, A., Coscia, A., Fabris, C., Aime, S., Belloni, C., Bossi, G., Salati, B., Boucher, C., Buffolano, W., Butler, K., Cabero Roura, L., Bertran Sanges, J. M., Cigna, P., Ciria, L. M., Servera Ginard, C., Claret Teruel, G., Fortuny, C., Coll, O., Corrias, A., Ledda, R., Floris, S., Maria, A., Echeverria, J., Cilla, G., Lanari, M., Tridapalli, E., Venturi, V., Faldella, G., Fischler, B., Bohlin, A. -B, Lindgren, S., Lindh, G., Giacomet, V., Merlo, M., Figini, C., Erba, P., Viganò, A., Hannam, S., Mieli-Vergani, G., Hatzakis, A., Inchley, C., Fjaerli, H. O., Maccabruni, A., Marcellini, M., Sartorelli, M. R., Martin Fontelos, P., Mazza, A., Mok, J. Y. Q., Mûr, A., Viñolas, M., Paternoster, D. M., Grella, P., Polywka, S., Quinti, I., Casadei, A. M., Rojahn, A., Berg, A., Rosso, R., Ferrando, S., Bassetti, D., Ruiz Contreras, J., Manzanares, A., Ruiz Extremera, A., Salvini, F., Gianvincenzo Zuccotti, Schmitz, T., Grosch-Wörner, I., Feiterna Sperling, C., Piening, T., Vegnente, A., Iorio, R., Versace, A., Garetto, S., Lazier, L., Bressio, S., Riva, C., Alfarano, A., Wejstal, R., Norkrans, G., Zanetti, A., Tanzi, E., Tovo, P. -A, Pembrey, L., and Newell, M. -L

48. Hamburger ALL-Studien

Author

Winkler, K., primary, Marsmann, G., additional, Grosch-Wörner, I., additional, Caspers, S., additional, Kabisch, H., additional, Matzke, E., additional, Meissner, C., additional, Müller, J., additional, Franke, H., additional, Langendorff, G., additional, Hess, A., additional, and Landbeck, G., additional

Published
1980
Full Text
View/download PDF

50. Malignes Melanom beim Kind - 2 Fallberichte*

Author

Fengler, R., primary, Pankrath, K., additional, Baumgarten, E., additional, Beck, C., additional, Becker, H., additional, Buchmann, S., additional, Grosch-Wörner, I., additional, Nessler, G., additional, Schuppert, W., additional, and Henze, G., additional

Published
1986
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results